NCT06795360Not yet recruiting
Weight Changes After Incretin-mimetics
Source: ClinicalTrials.gov · Last updated 24 Feb 2026
Brief summary (registry, in English)
The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- First submitted
- 22 Jan 2025
- Start date
- 1 Dec 2026
- Primary completion date
- 30 Nov 2031
- Lead sponsor
- Medical College of Wisconsin
- Diseases
- Obesity
- NCT number
- NCT06795360
What you commit to
- Study type: Interventional
- Planned participants: 52
- From 1 Dec 2026 to the primary completion date, 30 Nov 2031
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients taking steroid medications
- post solid organ or bone marrow transplant
- current recreational drug use
Other illness
- type 1 or type 2 diabetes
- heart disease
- advanced kidney disease (CKD stage 4 and 5)
- decompensated liver disease
- active cancer
- HIV/AIDS
Other
- weight \> or = 400 lb
- anemia
- hyperthyroidism
- untreated hypothyroidism
- pregnancy/plan for pregnancy in the next 6 months
- breastfeeding
- post-menopausal women
- current smoker
- night shift or rotating shift workers
Who the study is looking for
- adults 18 years or older
- men and women
- prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse
- any ethnicity
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.